公开(公告)号：US12297252B2

公开(公告)日：2025-05-13

申请号：US17354555

申请日：2021-06-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian Bunk ,  Dominik Maurer ,  Jens Fritsche ,  Claudia Wagner ,  Leonie Alten ,  Franziska Hoffgaard ,  Mathias Ferber

IPC: C07K14/725 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/09

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

公开(公告)号：US12295994B2

公开(公告)日：2025-05-13

申请号：US17937165

申请日：2022-09-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Jens Fritsche ,  Harpreet Singh ,  Andrea Mahr ,  Martina Ott ,  Claudia Wagner ,  Oliver Schoor

IPC: A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  C07K7/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250145684A1

公开(公告)日：2025-05-08

申请号：US19015015

申请日：2025-01-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Gisela SCHIMMACK ,  Annika SONNTAG ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/73 ,  A61K35/17 ,  A61K39/00 ,  C07K7/00 ,  C07K14/705 ,  C07K14/74 ,  C07K16/00 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250144192A1

公开(公告)日：2025-05-08

申请号：US19016817

申请日：2025-01-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/00 ,  A61K38/08 ,  A61K38/17 ,  A61K39/39 ,  A61K40/11 ,  A61K40/42 ,  A61P35/00 ,  A61P35/02 ,  C07K7/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/72 ,  C07K14/725 ,  C07K16/00 ,  C07K16/28 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12285443B2

公开(公告)日：2025-04-29

申请号：US18599860

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda Hannen ,  Jens Hukelmann ,  Florian Koehler ,  Daniel Johannes Kowalewski ,  Heiko Schuster ,  Oliver Schoor ,  Michael Roemer ,  Chih-Chiang Tsou ,  Jens Fritsche

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250122302A1

公开(公告)日：2025-04-17

申请号：US18989486

申请日：2024-12-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

公开(公告)号：US20250034227A1

公开(公告)日：2025-01-30

申请号：US18785378

申请日：2024-07-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Timo MANZ ,  Nadine ASCHMONEIT ,  Maike JAWORSKI ,  Lena SCHMOHL ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Nora TREIBER

IPC: C07K14/725 ,  A61K38/00 ,  A61P35/00

Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.

公开(公告)号：US12209137B2

公开(公告)日：2025-01-28

申请号：US17874711

申请日：2022-07-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Sara Yousef ,  Fabian Brunk ,  Andreas Moritz ,  Sebastian Bunk ,  Claudia Wagner ,  Dominik Maurer ,  Felix Unverdorben

IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

公开(公告)号：US12188932B2

公开(公告)日：2025-01-07

申请号：US16569691

申请日：2019-09-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andreas Moritz ,  Dominik Maurer ,  Sebastian Bunk ,  Claudia Wagner

IPC: A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/74 ,  G01N33/569 ,  G01N33/50

Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

公开(公告)号：US12186276B2

公开(公告)日：2025-01-07

申请号：US17727255

申请日：2022-04-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.